A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 7, 2015

Primary Completion Date

September 24, 2015

Study Completion Date

September 24, 2015

Conditions
Dermatitis, Atopic
Interventions
DRUG

Combination therapy GSK2894512 Cream A + GSK2894512 Cream B

GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm\^2 of skin.

DRUG

Combination therapy Vehicle Cream A + Vehicle Cream B

Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.

Trial Locations (1)

61801

GSK Investigational Site, Urbana

All Listed Sponsors
lead

Stiefel, a GSK Company

INDUSTRY

NCT02411162 - A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream | Biotech Hunter | Biotech Hunter